EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone
Progression‐free survival · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes progression‐free survival compared with chemotherapy alone (very low certainty).
1 finding from 1 review
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes onlyHR 0.99 [0.69, 1.42]1 study · 129 participantsVery low